Is LKFT or IMVT more profitable?

Lakefront Biotherapeutics American Depositary Shares' return on equity of 0.00% beat Immunovant's return on equity. Company Net Margins Return on Equity Return on Assets Lakefront Biotherapeutics American Depositary Shares N/A N/A N/A Immunovant N/A -65.66% -59.88%

Is SYRE or LKFT more profitable?

Lakefront Biotherapeutics American Depositary Shares' return on equity of 0.00% beat Spyre Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Spyre Therapeutics N/A -42.88% -27.76% Lakefront Biotherapeutics American Depositary Shares N/A N/A N/A

Lakefront Biotherapeutics American Depositary Shares (LKFT) Competitors

$30.59 -0.22 (-0.71%)

As of 04:00 PM Eastern

Compare

LKFT vs. PTGX, IMVT, SYRE, RYTM, and MIRM

Should you buy Lakefront Biotherapeutics American Depositary Shares stock or one of its competitors? MarketBeat compares Lakefront Biotherapeutics American Depositary Shares with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Lakefront Biotherapeutics American Depositary Shares include Protagonist Therapeutics (PTGX), Immunovant (IMVT), Spyre Therapeutics (SYRE), Rhythm Pharmaceuticals (RYTM), and Mirum Pharmaceuticals (MIRM). These companies are all part of the "pharmaceutical products" industry.

How does Lakefront Biotherapeutics American Depositary Shares compare to Protagonist Therapeutics?

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) and Protagonist Therapeutics (NASDAQ:PTGX) are both mid-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, media sentiment, dividends, profitability, analyst recommendations, valuation, institutional ownership and earnings.

In the previous week, Protagonist Therapeutics had 5 more articles in the media than Lakefront Biotherapeutics American Depositary Shares. MarketBeat recorded 7 mentions for Protagonist Therapeutics and 2 mentions for Lakefront Biotherapeutics American Depositary Shares. Lakefront Biotherapeutics American Depositary Shares' average media sentiment score of 0.55 beat Protagonist Therapeutics' score of 0.46 indicating that Lakefront Biotherapeutics American Depositary Shares is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lakefront Biotherapeutics American Depositary Shares	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Protagonist Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Lakefront Biotherapeutics American Depositary Shares presently has a consensus price target of $36.50, indicating a potential upside of 19.32%. Protagonist Therapeutics has a consensus price target of $116.93, indicating a potential downside of 15.05%. Given Lakefront Biotherapeutics American Depositary Shares' higher probable upside, research analysts plainly believe Lakefront Biotherapeutics American Depositary Shares is more favorable than Protagonist Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lakefront Biotherapeutics American Depositary Shares	1 Sell rating(s)	6 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.13
Protagonist Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.88

Lakefront Biotherapeutics American Depositary Shares has a beta of 0.25, meaning that its stock price is 75% less volatile than the broader market. Comparatively, Protagonist Therapeutics has a beta of 1.79, meaning that its stock price is 79% more volatile than the broader market.

32.5% of Lakefront Biotherapeutics American Depositary Shares shares are owned by institutional investors. Comparatively, 98.6% of Protagonist Therapeutics shares are owned by institutional investors. 2.9% of Lakefront Biotherapeutics American Depositary Shares shares are owned by insiders. Comparatively, 5.2% of Protagonist Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Lakefront Biotherapeutics American Depositary Shares has higher revenue and earnings than Protagonist Therapeutics. Protagonist Therapeutics is trading at a lower price-to-earnings ratio than Lakefront Biotherapeutics American Depositary Shares, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lakefront Biotherapeutics American Depositary Shares	$1.26B	1.60	$363.05M	-$1.41	N/A
Protagonist Therapeutics	$46.02M	192.34	-$130.15M	-$1.81	N/A

Lakefront Biotherapeutics American Depositary Shares has a net margin of 0.00% compared to Protagonist Therapeutics' net margin of -154.88%. Lakefront Biotherapeutics American Depositary Shares' return on equity of 0.00% beat Protagonist Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lakefront Biotherapeutics American Depositary Shares	N/A	N/A	N/A
Protagonist Therapeutics	-154.88%	-17.76%	-16.47%

Summary

Lakefront Biotherapeutics American Depositary Shares beats Protagonist Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Lakefront Biotherapeutics American Depositary Shares compare to Immunovant?

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) and Immunovant (NASDAQ:IMVT) are both mid-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, valuation, earnings, profitability, media sentiment, institutional ownership and dividends.

Lakefront Biotherapeutics American Depositary Shares has higher revenue and earnings than Immunovant. Lakefront Biotherapeutics American Depositary Shares is trading at a lower price-to-earnings ratio than Immunovant, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lakefront Biotherapeutics American Depositary Shares	$1.26B	1.60	$363.05M	-$1.41	N/A
Immunovant	N/A	N/A	-$505.61M	-$2.78	N/A

Lakefront Biotherapeutics American Depositary Shares presently has a consensus price target of $36.50, indicating a potential upside of 19.32%. Immunovant has a consensus price target of $39.70, indicating a potential downside of 3.38%. Given Lakefront Biotherapeutics American Depositary Shares' higher probable upside, equities research analysts plainly believe Lakefront Biotherapeutics American Depositary Shares is more favorable than Immunovant.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lakefront Biotherapeutics American Depositary Shares	1 Sell rating(s)	6 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.13
Immunovant	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.45

Lakefront Biotherapeutics American Depositary Shares' return on equity of 0.00% beat Immunovant's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lakefront Biotherapeutics American Depositary Shares	N/A	N/A	N/A
Immunovant	N/A	-65.66%	-59.88%

In the previous week, Immunovant had 3 more articles in the media than Lakefront Biotherapeutics American Depositary Shares. MarketBeat recorded 5 mentions for Immunovant and 2 mentions for Lakefront Biotherapeutics American Depositary Shares. Lakefront Biotherapeutics American Depositary Shares' average media sentiment score of 0.55 beat Immunovant's score of 0.47 indicating that Lakefront Biotherapeutics American Depositary Shares is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lakefront Biotherapeutics American Depositary Shares	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Immunovant	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Lakefront Biotherapeutics American Depositary Shares has a beta of 0.25, suggesting that its share price is 75% less volatile than the broader market. Comparatively, Immunovant has a beta of 0.76, suggesting that its share price is 24% less volatile than the broader market.

32.5% of Lakefront Biotherapeutics American Depositary Shares shares are owned by institutional investors. Comparatively, 47.1% of Immunovant shares are owned by institutional investors. 2.9% of Lakefront Biotherapeutics American Depositary Shares shares are owned by insiders. Comparatively, 1.8% of Immunovant shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Lakefront Biotherapeutics American Depositary Shares beats Immunovant on 9 of the 15 factors compared between the two stocks.

How does Lakefront Biotherapeutics American Depositary Shares compare to Spyre Therapeutics?

Spyre Therapeutics (NASDAQ:SYRE) and Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) are both mid-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, media sentiment, risk, institutional ownership, valuation, earnings and analyst recommendations.

80.4% of Spyre Therapeutics shares are owned by institutional investors. Comparatively, 32.5% of Lakefront Biotherapeutics American Depositary Shares shares are owned by institutional investors. 15.7% of Spyre Therapeutics shares are owned by company insiders. Comparatively, 2.9% of Lakefront Biotherapeutics American Depositary Shares shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Lakefront Biotherapeutics American Depositary Shares' return on equity of 0.00% beat Spyre Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spyre Therapeutics	N/A	-42.88%	-27.76%
Lakefront Biotherapeutics American Depositary Shares	N/A	N/A	N/A

Spyre Therapeutics has a beta of 3.02, meaning that its stock price is 202% more volatile than the broader market. Comparatively, Lakefront Biotherapeutics American Depositary Shares has a beta of 0.25, meaning that its stock price is 75% less volatile than the broader market.

In the previous week, Spyre Therapeutics had 3 more articles in the media than Lakefront Biotherapeutics American Depositary Shares. MarketBeat recorded 5 mentions for Spyre Therapeutics and 2 mentions for Lakefront Biotherapeutics American Depositary Shares. Lakefront Biotherapeutics American Depositary Shares' average media sentiment score of 0.55 beat Spyre Therapeutics' score of -0.16 indicating that Lakefront Biotherapeutics American Depositary Shares is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Spyre Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Lakefront Biotherapeutics American Depositary Shares	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Lakefront Biotherapeutics American Depositary Shares has higher revenue and earnings than Spyre Therapeutics. Spyre Therapeutics is trading at a lower price-to-earnings ratio than Lakefront Biotherapeutics American Depositary Shares, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spyre Therapeutics	$890K	9,757.39	-$155.20M	-$2.08	N/A
Lakefront Biotherapeutics American Depositary Shares	$1.26B	1.60	$363.05M	-$1.41	N/A

Spyre Therapeutics presently has a consensus price target of $95.83, suggesting a potential downside of 2.95%. Lakefront Biotherapeutics American Depositary Shares has a consensus price target of $36.50, suggesting a potential upside of 19.32%. Given Lakefront Biotherapeutics American Depositary Shares' higher probable upside, analysts plainly believe Lakefront Biotherapeutics American Depositary Shares is more favorable than Spyre Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spyre Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00
Lakefront Biotherapeutics American Depositary Shares	1 Sell rating(s)	6 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.13

Summary

Spyre Therapeutics and Lakefront Biotherapeutics American Depositary Shares tied by winning 8 of the 16 factors compared between the two stocks.

How does Lakefront Biotherapeutics American Depositary Shares compare to Rhythm Pharmaceuticals?

Rhythm Pharmaceuticals (NASDAQ:RYTM) and Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) are both mid-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, profitability, risk, analyst recommendations, institutional ownership and media sentiment.

32.5% of Lakefront Biotherapeutics American Depositary Shares shares are owned by institutional investors. 5.9% of Rhythm Pharmaceuticals shares are owned by company insiders. Comparatively, 2.9% of Lakefront Biotherapeutics American Depositary Shares shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Lakefront Biotherapeutics American Depositary Shares has higher revenue and earnings than Rhythm Pharmaceuticals. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Lakefront Biotherapeutics American Depositary Shares, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rhythm Pharmaceuticals	$189.76M	41.70	-$196.54M	-$3.13	N/A
Lakefront Biotherapeutics American Depositary Shares	$1.26B	1.60	$363.05M	-$1.41	N/A

Rhythm Pharmaceuticals has a beta of 1.88, meaning that its stock price is 88% more volatile than the broader market. Comparatively, Lakefront Biotherapeutics American Depositary Shares has a beta of 0.25, meaning that its stock price is 75% less volatile than the broader market.

Lakefront Biotherapeutics American Depositary Shares has a net margin of 0.00% compared to Rhythm Pharmaceuticals' net margin of -93.33%. Lakefront Biotherapeutics American Depositary Shares' return on equity of 0.00% beat Rhythm Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rhythm Pharmaceuticals	-93.33%	-203.25%	-44.99%
Lakefront Biotherapeutics American Depositary Shares	N/A	N/A	N/A

Rhythm Pharmaceuticals currently has a consensus price target of $136.40, indicating a potential upside of 18.12%. Lakefront Biotherapeutics American Depositary Shares has a consensus price target of $36.50, indicating a potential upside of 19.32%. Given Lakefront Biotherapeutics American Depositary Shares' higher probable upside, analysts clearly believe Lakefront Biotherapeutics American Depositary Shares is more favorable than Rhythm Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rhythm Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.76
Lakefront Biotherapeutics American Depositary Shares	1 Sell rating(s)	6 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.13

In the previous week, Lakefront Biotherapeutics American Depositary Shares had 1 more articles in the media than Rhythm Pharmaceuticals. MarketBeat recorded 2 mentions for Lakefront Biotherapeutics American Depositary Shares and 1 mentions for Rhythm Pharmaceuticals. Lakefront Biotherapeutics American Depositary Shares' average media sentiment score of 0.55 beat Rhythm Pharmaceuticals' score of 0.00 indicating that Lakefront Biotherapeutics American Depositary Shares is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rhythm Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Lakefront Biotherapeutics American Depositary Shares	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Lakefront Biotherapeutics American Depositary Shares beats Rhythm Pharmaceuticals on 12 of the 17 factors compared between the two stocks.

How does Lakefront Biotherapeutics American Depositary Shares compare to Mirum Pharmaceuticals?

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) and Mirum Pharmaceuticals (NASDAQ:MIRM) are both mid-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, risk, valuation, media sentiment, analyst recommendations, institutional ownership and dividends.

Lakefront Biotherapeutics American Depositary Shares has higher revenue and earnings than Mirum Pharmaceuticals. Lakefront Biotherapeutics American Depositary Shares is trading at a lower price-to-earnings ratio than Mirum Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lakefront Biotherapeutics American Depositary Shares	$1.26B	1.60	$363.05M	-$1.41	N/A
Mirum Pharmaceuticals	$521.31M	14.94	-$23.36M	-$13.61	N/A

In the previous week, Mirum Pharmaceuticals had 9 more articles in the media than Lakefront Biotherapeutics American Depositary Shares. MarketBeat recorded 11 mentions for Mirum Pharmaceuticals and 2 mentions for Lakefront Biotherapeutics American Depositary Shares. Mirum Pharmaceuticals' average media sentiment score of 0.56 beat Lakefront Biotherapeutics American Depositary Shares' score of 0.55 indicating that Mirum Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lakefront Biotherapeutics American Depositary Shares	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Mirum Pharmaceuticals	7 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

32.5% of Lakefront Biotherapeutics American Depositary Shares shares are owned by institutional investors. 2.9% of Lakefront Biotherapeutics American Depositary Shares shares are owned by insiders. Comparatively, 8.3% of Mirum Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Lakefront Biotherapeutics American Depositary Shares has a net margin of 0.00% compared to Mirum Pharmaceuticals' net margin of -140.24%. Lakefront Biotherapeutics American Depositary Shares' return on equity of 0.00% beat Mirum Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lakefront Biotherapeutics American Depositary Shares	N/A	N/A	N/A
Mirum Pharmaceuticals	-140.24%	-11.28%	-3.84%

Lakefront Biotherapeutics American Depositary Shares currently has a consensus target price of $36.50, indicating a potential upside of 19.32%. Mirum Pharmaceuticals has a consensus target price of $143.40, indicating a potential upside of 12.29%. Given Lakefront Biotherapeutics American Depositary Shares' higher possible upside, research analysts plainly believe Lakefront Biotherapeutics American Depositary Shares is more favorable than Mirum Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lakefront Biotherapeutics American Depositary Shares	1 Sell rating(s)	6 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.13
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93

Lakefront Biotherapeutics American Depositary Shares has a beta of 0.25, meaning that its share price is 75% less volatile than the broader market. Comparatively, Mirum Pharmaceuticals has a beta of 0.48, meaning that its share price is 52% less volatile than the broader market.

Summary

Lakefront Biotherapeutics American Depositary Shares and Mirum Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.

Get Lakefront Biotherapeutics American Depositary Shares News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LKFT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LKFT vs. The Competition

Export

Metric	Lakefront Biotherapeutics American Depositary Shares	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.03B	$3.78B	$6.93B	$12.49B
Dividend Yield	N/A	2.18%	2.68%	7.79%
P/E Ratio	-21.70	21.70	27.39	24.62
Price / Sales	1.60	328.99	549.66	113.75
Price / Cash	42.43	145.39	48.45	59.17
Price / Book	0.64	8.62	11.02	6.46
Net Income	$363.05M	$23.85M	$3.57B	$331.60M
7 Day Performance	0.66%	0.94%	0.41%	-0.42%
1 Month Performance	8.21%	12.09%	5.76%	2.09%
1 Year Performance	2.48%	57.06%	31.25%	22.24%

Lakefront Biotherapeutics American Depositary Shares Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LKFT Lakefront Biotherapeutics American Depositary Shares	2.0258 of 5 stars	$30.59 -0.7%	$36.50 +19.3%	+6.9%	$2.03B	$1.26B	N/A	1,310
PTGX Protagonist Therapeutics	1.0735 of 5 stars	$122.95 +1.1%	$115.21 -6.3%	+181.8%	$7.91B	$46.02M	N/A	120	News Coverage Analyst Forecast
IMVT Immunovant	1.3799 of 5 stars	$38.52 +0.0%	$37.33 -3.1%	+138.7%	$7.91B	N/A	N/A	120	Analyst Forecast Insider Trade
SYRE Spyre Therapeutics	1.2841 of 5 stars	$91.10 +1.0%	$95.83 +5.2%	+511.1%	$7.88B	$890K	N/A	73
RYTM Rhythm Pharmaceuticals	1.7108 of 5 stars	$110.51 +0.4%	$133.13 +20.5%	+75.7%	$7.59B	$189.76M	N/A	140	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LKFT) was last updated on 7/9/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Lakefront Biotherapeutics American Depositary Shares (LKFT) Competitors

LKFT vs. PTGX, IMVT, SYRE, RYTM, and MIRM

How does Lakefront Biotherapeutics American Depositary Shares compare to Protagonist Therapeutics?

Summary

How does Lakefront Biotherapeutics American Depositary Shares compare to Immunovant?

Summary

How does Lakefront Biotherapeutics American Depositary Shares compare to Spyre Therapeutics?

Summary

How does Lakefront Biotherapeutics American Depositary Shares compare to Rhythm Pharmaceuticals?

Summary

How does Lakefront Biotherapeutics American Depositary Shares compare to Mirum Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LKFT vs. The Competition

Lakefront Biotherapeutics American Depositary Shares Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Lakefront Biotherapeutics American Depositary Shares (LKFT) Competitors

LKFT vs. PTGX, IMVT, SYRE, RYTM, and MIRM

How does Lakefront Biotherapeutics American Depositary Shares compare to Protagonist Therapeutics?

Does the media favor LKFT or PTGX?

Do analysts recommend LKFT or PTGX?

Which has more volatility and risk, LKFT or PTGX?

Do insiders and institutionals believe in LKFT or PTGX?

Which has preferable earnings & valuation, LKFT or PTGX?

Is LKFT or PTGX more profitable?

Summary

How does Lakefront Biotherapeutics American Depositary Shares compare to Immunovant?

Which has higher earnings and valuation, LKFT or IMVT?

Do analysts rate LKFT or IMVT?

Is LKFT or IMVT more profitable?

Does the media favor LKFT or IMVT?

Which has more volatility and risk, LKFT or IMVT?

Do institutionals and insiders hold more shares of LKFT or IMVT?

Summary

How does Lakefront Biotherapeutics American Depositary Shares compare to Spyre Therapeutics?

Do institutionals and insiders hold more shares of SYRE or LKFT?

Is SYRE or LKFT more profitable?

Which has more volatility & risk, SYRE or LKFT?

Does the media favor SYRE or LKFT?

Which has preferable earnings & valuation, SYRE or LKFT?

Do analysts recommend SYRE or LKFT?

Summary

How does Lakefront Biotherapeutics American Depositary Shares compare to Rhythm Pharmaceuticals?

Do institutionals & insiders have more ownership in RYTM or LKFT?

Which has higher earnings and valuation, RYTM or LKFT?

Which has more volatility & risk, RYTM or LKFT?

Is RYTM or LKFT more profitable?

Do analysts rate RYTM or LKFT?

Does the media refer more to RYTM or LKFT?

Summary

How does Lakefront Biotherapeutics American Depositary Shares compare to Mirum Pharmaceuticals?

Which has preferable valuation and earnings, LKFT or MIRM?

Does the media refer more to LKFT or MIRM?

Do insiders & institutionals have more ownership in LKFT or MIRM?

Is LKFT or MIRM more profitable?

Do analysts rate LKFT or MIRM?

Which has more volatility and risk, LKFT or MIRM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LKFT vs. The Competition

Lakefront Biotherapeutics American Depositary Shares Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools